

4. REFERENCES

REFERENCES

1. Berner B and Kydonieus A; Novel Drug Delivery Systems, in Welling PG, Lasagna L and Banakar U, eds., *The Drug Development Process: Increasing Efficiency and Cost-effectiveness*. Marcel Dekker Series, Vol. 76, NY 1996, pp. 170-201.
2. Pargal A; "Oral Controlled Release Drug Delivery Systems - a perspective" Chapter 7, in Vyas JN and Shah G eds. *Saket Pharma Handbook*, Saket Projects Ltd., 1997, pp. 427-435.
3. Higuchi WI; "Status of the Drug Delivery Field from an Academic Pharmaceuticals Viewpoint" in Roseman TJ ed., *Controlled Release Newsletter*, 13(1), April 1996, Controlled Release Society, Inc, USA.
4. Bhalla HL; "New Drug Delivery Systems: The vast untapped potential" in *Express Pharma Pulse*, Special issue with Vol. 3(38), August 14, 1997, pp. 16, 34.
5. Bhalla HL; "Status of Drug Delivery Systems in India" in the souvenir of the 3rd International Symposium on Innovations in Pharmaceutical Sciences and Technology, 7-9th February, 1997, held at the B. V. Patel PERD Centre, Ahmedabad, INDIA, pp. 67-71.
6. Valia KH; Oral Controlled Release Drug Delivery Systems: A Review of the Patent Literature. Presented at the Presymposium Workshop on Oral Controlled Drug Delivery, February 5-6, 1997, at the B. V. Patel PERD Centre, Ahmedabad, INDIA.
7. Florence AT and Jani PU; Novel oral drug formulations: Their potential in modulating adverse effects. *Drug Safety*: 10(3), (1994), 233-236.
8. Kurowski M; The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. *Int. J. Clin. Pharm. Ther.* 32(8), (1994), 433-440.
9. Zingerman JR, Cardinal JR, Chern RT, Holste J, Williams JB, Eckenhoff B and Wright J; The *in vitro* and *in vivo* performance of an osmotically controlled delivery system, Ivomec-SR. *J. Control. Rel.* 47(1), (1997), 1-11.
10. Bodde HE, deVries ME and Verhoef JL; Developments in buccal drug delivery. *Crit. Rev. Therap. Drug Carr. Syst.*: 8, (1991), 271-303.
11. Chien YW, Nozaki Y and Ohta M; Transmucosal controlled systemic delivery of ISDN: *in-vivo/in-vitro* correlation. *J. Control. Rel.*: 43(2&3), (1997), 105-114.

12. Guo JH and Cooklock KM; The effects of backing materials and multilayered systems on the characteristics of bioadhesive buccal patches. *J. Pharm. Pharmacol.*: 48(3), (1996), 255-257.
13. Senel S, Capan Y, Sargan MF, Ilinci G, Solpan D, Guven O, Bodde HE and Hincal AA; Enhancement of transbuccal permeation of morphine sulphate by sodium glucodeoxycholate *in-vitro*. *J. Control. Rel.*: 45(2), (1997), 153-162.
14. Ashford M; Targeting drugs to the colon: Delivery systems for oral administration. *J. Drug Target.* 2(3), (1994), 241-257.
15. Rubinstein A; Approaches and opportunities in colon-specific drug delivery. *Crit. Rev. Therap. Drug Carrier Syst.*: 12(2&3), (1995), 101-149.
16. Friend DR; Colon specific drug delivery. *Adv. Drug Del. Rev.* 7, (1991), 149-199.
17. Schacht E, Gevaert A, Kenawy ER, Molly K, Verstraete W, Adriansens P, Carleer R and Gelan J; Polymers for colon-specific drug delivery. (5-ASA) *J. Control. Rel.* 39, (1996), 327-338.
18. Haeberlin B; *In-vitro* evaluation of dexamethasone- β -D-glucuronide for colon specific drug delivery. *Pharm. Res.*: 10(11), (1993), 1553-1562.
19. Kalala W, Kinget R, van der Mooter G and Samyn C; Colonic drug-targeting: *In-vitro* release of ibuprofen from capsules coated with poly(ether-ester) azopolymers. *Int. J. Pharm.*: 139(2), (1996), 187-195.
20. Cheng CL, Geharke SH and Ritschel WA; Development of an azopolymer based colonic release capsule for delivering proteins and macromolecules. *Meth. Find. Exp. Clin. Pharmacol.*: 16(4), (1994), 271-278.
21. Adkin DA, Kenyon CJ, Lerner I, Strauss E, Caron D, Penhasi A, Rubinstein A and Wilding IR; The use of scintigraphy to provide "Proof of Concept" for novel polysaccharide preparations designed for colonic drug delivery. *Pharm. Res.* 14(1), (1997), 103-107.
22. Bronsted H; Hydrogels for the site-specific drug delivery to the colon: *in vitro* and *in vivo* degradation. *Pharm. Res.* 9(2), (1992), 1540-1545.
23. Rubinstein A, Tirosh B, Baluom M, Nassar T, David A, Radai R, Gliko-Kabir I and Friedamn M; The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. *J. Control. Rel.*: 46(1-2), (1997), 59-73.

24. Thadani U and Lipicky RJ; Ointments and transdermal patches for stable angina pectoris. *Drugs Ther.*: 8(4), (1994), 625-633.
25. Singh S and Singh J; Transdermal drug delivery by passive diffusion and iontophoresis: a review. *Med. Res. Rev.* 13(5), (1993), 569-621.
26. Banga AK; Hydrogel based iontotherapeutic delivery device for transdermal delivery of peptide/protein drugs. *Pharm. Res.* 10(5), (1993), 697-702.
27. Haga M, Akatani M, Kikuchi J, Ueno Y, Hayashi M; Transdermal iontophoretic delivery of insulin using a photoetched microdevice. *J. Control. Rel.*: 43(2&3), (1997), 139-149.
28. Chou W-L, Cheng C-H, Yen S-C and Jiang T-S; The enhanced iontophoretic transport of TRH and its impedance study. *Drug Dev. Ind. Pharm.*: 22(9&10), (1996), 943-950.
29. McCartin C, Hutchison LEF, Hyde R and Peters GE; Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. *J. Pharm. Sci.* 76, (1987), 535-540.
30. Illum L, Farraj NF and Davis SS; Chitosan as a novel nasal delivery system for peptide drugs. *Pharm. Res.*: 11, (1994), 1186-1189.
31. Ascentiis AD, Bettini R, Caponetti G, Catellani PL, Peracchia MT, Santi P and Colombo P; Delivery of nasal powders of β -cyclodextrin by insufflation. *Pharm. Res.*: 13(5), (1996), 734-738.
32. Smith PL; Peptide delivery via the pulmonary route: A valid approach for local and systemic delivery. *J. Control. Rel.*: 46(1-2), (1997), 99-106.
33. Morita T, Yamamoto A, Takakura Y, Hashida M and Sezaki H; Improvement of the pulmonary absorption of (Asu^{1,7})-Eel calcitonin by various protease inhibitors in rats. *Pharm. Res.*: 11(6), (1994), 909-913.
34. Martonen TB and Katz IM; Deposition patterns of aerosolized drugs within the human lungs. *Pharm. Res.*: 10, (1993), 871-878.
35. Weidmann TS, DeCastro L and Wood RW; Nebulization of NanoCrystalsTM: Production of a respirable solid-in-liquid-in-air colloidal dispersion. *Pharm. Res.*: 14(1), (1997), 112-116.
36. Hiroaki O; Biodegradable microspheres in drug delivery. *Crit. Rev. Therap. Drug Carrier Syst.*: 12(1), (1995), 1-99.

37. Gopferich A; Bioerodible implants with programmable drug release. *J. Control. Rel.*: 44(2&3), (1997), 271-281.
38. Okada H and Toguchi H; Biodegradable microspheres in drug delivery. *Crit. Rev. Ther. Drug Carr. Syst.* 12(1), (1995), 1-99.
39. Piskin E; Biodegradable polymers as biomaterials. *J. Biomater. Sci. Polymer Edn.*, 6(9), (1994), 775-795.
40. Conti B; Use of poly-lactic acid for the preparation of microparticulate systems. *J. Microencap.* 9(2), (1992), 153-166.
41. Thomas PA, Pádmaja T, Kulkarni MG; Polyanhydride blend microspheres: Novel carriers for the controlled release of macromolecular drugs. *J. Control. Rel.*: 43(2&3), (1997), 273-281.
42. Du J, Jasti B and Vasavda RC; Controlled-release of tobramycin from poly(ortho esters) implantable discs for the treatment of osteomyelitis. *J. Control. Rel.*: 43(2&3), (1997), 223-233.
43. Gurny R, Tabatabay C, Bernatchez SF, Merkli A, Allemann E, Lescure F and Doelker E; Biodegradable polymers: Contemporary issues and new directions. *Eur. J. Hosp. Pharm.*: 3(1), (1993), 15-20.
44. Weiner N, Martin F and Riaz M; Liposomes as a drug delivery system. *Drug Dev. Ind. Pharm.* 15(10), (1989), 1523-1554.
45. Margalit R; Liposomes: Drug delivery and beyond. in Roseman TJ ed., *Controlled Release Newsletter* 13(2), June 1996, pp. 12-14, Controlled Release Society, Inc., USA.
46. Crommelin DJA, Daemen T, Scherphof GL, Vingerhoeds MH, Heeremans JLM, Kluft C and Storm G; Liposomes: Vehicles for the targeted and controlled delivery of peptide and proteins. *J. Control. Rel.* 46(1&2), (1997), 165-175.
47. Marjan JMJ and Allen TM; Long circulating liposomes: Past, present and future. *Biotechnology Advances* 14(2), (1996), 151-175.
48. Allen TM; Long-circulating (sterically stabilized) liposomes for targeted drug delivery. *Trends Pharmacol. Sci.* 15(7), (1994), 215-220.
49. Gurny R, Ibrahim H, Aebi A, Buri P, Wilson CG, Washington N, Edman P and Camber O; Design and evaluation of controlled release systems for the eye. *J. Control. Rel.*: 6, (1987), 367-373.

50. Ludwig A and Van Ooteghem M; The study of the precorneal dynamics of ophthalmic solutions by fluorophotometry. *Pharm. Acta Helv. Nr. 8*, (1986), 3-7.
51. Robinson JC; "Ocular anatomy and physiology relevant to ocular drug delivery", Chapter 2, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series*, Vol. 58, Marcel Dekker, Inc., 1993, pp. 29-27.
52. "The eye", Chapter 58, in Guyton AC ed., *Textbook of Medical Physiology*, 5th ed., W.B. Saunders Co., 1976, pp. 788.
53. Mastman GL, Blades EJ and Henderson JW; The total osmotic pressure of tears in normal and various pathological conditions. *Arch. Ophthalmol.*: 65, (1961), 509-516.
54. Holly FJ; Tear film physiology. *Int. Ophthalmol. Clin.* 27(1), (1987), 2-6.
55. Smolin G; The role of tears in the prevention of infections. *Int. Ophthalmol. Clin.* 27(1), (1987), 25-26.
56. Brieman JA and Snell C; The mechanisms of lacrimal flow. *Ophthalmologica*: 159, (1969), 223-229.
57. Silverman HI; Drugs and the eyes. *Drug Cos. Ind.*: May 1972, 44, 45, 139, 141.
58. Friedrich SW, Cheng YL and Saville BA; Theoretical corneal permeation model for ionizable drugs. *J. Ocul. Pharmacol.* 9(3), Fall (1993), 229-249.
59. Maurice DM; Factors influencing the penetration of topically applied drugs. *Int. Ophthalmol. Clin.*: 33(4), (1993), 21-32.
60. Nagataki S and Mishima S; Pharmacokinetics of instilled drugs in the human eye. *Int. Ophthalmol. Clin.*: 33(4), (1993), 33-49.
61. Olejnik O, Stevens J, Wilson CG, Hardy JG and Fisons PLC; Assessment of precorneal drainage of ophthalmic products by lacrimal scintigraphy. *J. Pharm. Pharmacol.*: (1982), 28P.
62. Makoid MC, Sieg JW and Robinson JR; Corneal drug absorption: An illustration of parallel first-order absorption and rapid loss of drug from absorption depot. *J. Pharm. Sci.*: 65(1), (1976), 150-151.
63. Lee VHL; "Precorneal, corneal and postcorneal factors", Chapter 3, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series*, Vol. 58, Marcel Dekker, Inc., 1993, pp. 59-81. 62(7), (1973), 1112-1121.

64. Patton TF and Ahmed I; Importance of non-corneal absorption route in topical drug delivery. *Invest. Ophthalmol. Vis. Sci.*: 26, (1985), 584-592.
65. Schoenwald RD; Ocular drug delivery: Pharmacokinetic considerations *Clin. Pharmacokinet.* 18(4), (1990), 255-269.
66. Maurice DM; Structures and fluids involved in the penetration of topically applied drugs. *Int. Ophthalmol. Clin.*: 33(4), (1993), 7-20.
67. Mishima S, Clinical pharmacokinetics of the eye. *Invest. Ophthalmol. Vis. Sci.*: 21, (1981), 504-541.
68. Patton TF, Ahmed I, Gokhale RD and Shah MV; Physicochemical determinants of drug diffusion across the conjunctiva, sclera and cornea. *J. Pharm. Sci.*: 76, (1987), 583-586.
69. Rojanasakul Y and Robinson JR; Transport mechanisms of the cornea: characterization of barrier permselectivity. *Int. J. Pharm.*: 55(2-3), (1989), 237-246.
70. Huang AJW, Tseng SCG and Kenyon KR; Paracellular permeability of corneal and conjunctival epithelia. *Invest. Ophthalmol. Vis. Sci.*: 30, (1989), 684-689.
71. Schoenwald RD; "Ocular pharmacokinetics/pharmacodynamics", Chapter 4, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series*, Vol. 58, Marcel Dekker, Inc., 1993, pp. 83-110.
72. Doane MG, Jensen AD and Dohlman CH; Penetration routes of topically applied eye medications. *Am. J. Ophthalmol.*: 85, (1978), 383-386.
73. Moroi SE and Lichter PR; "Ocular Pharmacology", Chapter 65, in Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 9th edition, McGraw Hill, 1995, pp. 1619-1645.
74. Urtti A and Salminen L; Minimizing systemic absorption of topically administered ophthalmic drugs. *Surv. Ophthalmol.*: 37(6), (1993), 435-456.
75. Meseguer G, Gurny R, Buri P, Rozier A and Plazonnet B; Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine. *Int. J. Pharm.*: 95, (1993), 229-234.
76. Fitzgerald P, Hadgraft J, Kreuter J and Wilson CG; A τ -scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. *Int. J. Pharm.*: 40, (1987), 81-84.

77. Fitzgerald P, Wilson CG, Greaves JL, Frier M, Hollingsbee D, Gilbert D and Richardson M; Scintigraphic assessment of the precorneal residence of a new ophthalmic delivery system (NODS) in man. *Int. J. Pharm.*: 83, (1992), 177-185.
78. Maurice DM and Srinivas SP; Use of fluorometry in assessing the efficacy of a cation-sensitive gel as an ophthalmic vehicle: Comparison with scintigraphy. *J. Pharm. Sci.*: 81(7), (1992), 615-619.
79. Ludwig A and Van Ooteghem M; The evaluation of viscous ophthalmic vehicles by slit lamp fluorophotometry in humans. *Int. J. Pharm.*: 54, (1989), 95-102.
80. Riegelman S and Sorby DL; "EENT Preparations", Chapter 16, in Martin EW ed., Husa's Pharmaceutical Dispensing, 6th edition, Mack Publishing Co., 1966, pp. 311-341.
81. "Ophthalmic Products" in Lund W. ed., The Pharmaceutical Codex, 12th edition: The Principles and Practice of Pharmaceutics., The Pharmaceutical Press, 1994, pp. 160-169.
82. Doane MG; Methods of ophthalmic fluid delivery. *Int. Ophthalmol. Clin.*: 33(5), (1993), 93-101.
83. Mackeen DL; Aqueous formulations and ointments. *Int. Ophthalmol. Clin.*: 33(5), (1993), 79-92.
84. Hardberger R, Hanna C and Boyd CM; Effects of drug vehicles on ocular contact time. *Arch. Ophthalmol.*: 93, (1975), 42-45.
85. Olejnik O; "Conventional Systems in Ophthalmic Drug Delivery", Chapter 9, in Mitra AK ed., Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series, Vol. 58, Marcel Dekker, Inc., 1993, pp. 177-198.
86. Rieger G; Lipid-containing eye-drops: A step closer to natural tears. *Ophthalmologica*: 201, (1990), 206-212.
87. Cohen T, Sauvageon-Martre H, Brossard D, D'Hermies F, Bardin C, Chast F and Chaumeil JC; Amphotericin-B eye drops as a lipidic emulsion. *Int. J. Pharm.*: 137, (1996), 249-254.
88. Hecht G, Roehrs RE, Lang JC, Rodeheaver DP and Chowhan MA; "Design and Evaluation of Ophthalmic Pharmaceuticals Products" Chapter 13, in Banker GS and Rhodes CT eds., Modern Pharmaceutics, 3rd edition, Marcel Dekker, Drugs and Pharmaceutical Sciences Series Vol. 72, 1996, pp. 489-546.
89. Naidoo T; Semi-solid ophthalmic dosage forms. *South African Journal of Pharmacy*: (1993), 356-359.

90. Greaves JL, Wilson CG and Birmingham AT; Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects. *Br. J. Ophthalmol.* 35, (1993), 188-192.
91. Krishnamoorthy R and Mitra AK; "Mucoadhesive polymers in Ocular Drug Delivery", Chapter 10, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series*, Vol. 58, Marcel Dekker, Inc., 1993, pp. 199-221.
92. Maurice DM; Prolonged-action drops. *Int. Ophthalmol. Clin.*: 33(4), Fall, (1993), 81-91.
93. Liesegang TJ; Viscoelastics. *Int. Ophthalmol. Clin.* 33(4), Fall, (1993), 127-147.
94. Gianaccini B and Alderigi C; Semisolid ophthalmic vehicles. *Boll. Chim. Farm.* 128(9), (1989), 257-266.
95. Saettone MF, Monti D, Torracca MT and Chetoni P; Mucoadhesive ophthalmic vehicles: Evaluation of polymeric low-viscosity formulations. *J. Ocul. Pharmacol.*: 10(1), (1994), 83-92.
96. Onlu N, Ludwig A, Van Ooteghem M and Hincal AA; A comparative rheological study on carbopol viscous solutions and, the evaluation of their suitability as the ophthalmic vehicles and artificial tears. *Pharm. Acta Helv.*: 67, Nr. 1, (1992), 5-10.
97. Bottari F, Giannaccini B, Peverini D, Saettone MF and Tellini N; Semisolid ophthalmic vehicles II: Evaluation in albino rabbits of aqueous gel-type vehicles containing lidocaine and benzocaine. *Can. J. Pharm. Sci.*: 14(2), (1979), 39-43.
98. Rozier A, Mazuel C, Grove J and Plazonnet B; Gelrite^R: A novel ion-activated *in situ* gelling polymer for ophthalmic vehicles: Effect on the bioavailability of timolol. *Int. J. Pharm.*: 57, (1989), 163-168.
99. Sanzgiri YD, Maschi S, Crescenzi V, Callegro L, Topp EM and Stella VJ; Gellan-based systems for ophthalmic sustained delivery of methylprednisolone. *J. Control. Rel.*: 26, (1993), 195-201.
100. Kumar S, Haglund B and Himmelstein KJ; *In situ* gels from combination of pH-sensitive and temperature-sensitive polymers. *Proc. Intern. Symp. Control. Rel. Bioact. Mater.*, 20(1993), 34-35.
101. Miller SC and Donovan MD; Effect of Poloxamer 407 gel in the miotic activity of pilocarpine nitrate in rabbits. *Int. J. Pharm.*: 12, (1982), 147-152.

102. Robinson JR and Mlynek GM; Bioadhesive and phase-change polymers for ocular drug delivery. *Adv. Drug Del. Rev.* 16, (1995), 45-50.
103. Gurny R, Zignani M and Tabatabay C; Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. *Adv. Drug Del. Rev.* 16, (1995), 51-60.
104. Bawa R; "Ocular inserts", Chapter 11, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series, Vol. 58, Marcel Dekker, Inc., 1993, pp. 223-260.*
105. Lamberts DW; Solid delivery devices. *Int. Ophthalmol. Clin.*: 33(5), (1993), 63-77.
106. Leshner GA and Gunderson GG; Continuous drug delivery through the use of disposable contact lenses. *Optom. Vis. Sci.* 70(12), (1993), 1012-1018.
107. Pearson PA, Jaffe GJ, Martin DF, Cordahi GJ, Grossniklaus H, Schmeisser ET and Ashton P; Evaluation of a delivery system providing long-term release of cyclosporine. *Arch. Ophthalmol.*: 114, (1996), 311-317.
108. Freidrich RL; The pilocarpine Ocuser: A new drug delivery system. *Ann. Ophthalmol.* 6, (1974), 12.
109. Bloomfield SE, Dunn MW, Miyata T, Stenzel KH, Randle SS and Rubin AL; Soluble artificial tear inserts. *Arch. Ophthalmol.*: 95, (1977), 247-250.
110. Katz IM and Blackman WM; A soluble sustained-release ophthalmic delivery unit. *Am. J. Ophthalmol.*: 83(5), (1977), 728-734.
111. Makoid MC, Cobby J and Grass GM; Ocular delivery of pilocarpine from erodible matrices. *J. Pharm. Sci.*: 73(5), (1984), 618-619.
112. Johnston WH, Wellish KL, Beltran F and Mondino BJ; Collagen shields. *Int. Ophthalmol. Clin.* 33(4), (1993), 93-107.
113. Hill JM, O'Callaghan RJ, Hobden JA and Kaufman HE; "Corneal collagen shields for ocular delivery", Chapter 12, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series, Vol. 58, Marcel Dekker, Inc., 1993, pp. 261-273.*
114. Sawusch MR, O'Brien TP, Dick JD and Gottsch JD; Use of corneal collagen shields in the treatment of bacterial keratitis. *Am. J. Ophthalmol.*: 106, (1988), 279-281.

115. Pamel GJ and Perl T; Collagen shield delivery of ciprofloxacin in uninflamed eyes. *Invest. Ophthalmol. Vis. Sci.* 34(4), (1993), Abstract No. 769-76.
116. Callegan MC, Engel LS, Clinch TE, Hill JM, Kaufman HE and O'Callaghan RJ; Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. *Curr. Eye Res.*: 13, (1994), 875-878.
117. "New method of ocular delivery launched". News item in *The Pharmaceutical Journal*, February 6, 1993, pp. 174.
118. Richardson MC and Bentley PH; "A new ophthalmic delivery system", Chapter 17, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series*, Vol. 58, Marcel Dekker, Inc., 1993, pp. 355-367.
119. Kreuter J; Particulates (Nanoparticles and microparticles). Chapter 13, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series*, Vol. 58, Marcel Dekker, Inc., 1993, pp. 275-287.
120. Gurny R, Boye T and Ibrahim H; Ocular therapy with nanoparticulate system for controlled drug delivery. *J. Control. Rel.*: 2, (1985), 353-361.
122. Losa C, Marchal-Heussler L, Orallo F, Vila-Jato JL and Alonso MJ; Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. *Pharm. Res.*: 10, (1993), 80-87.
123. Zimmer AK, Maincent P, Thouvenot P and Kreuter J; Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles. *Int. J. Pharm.*: 110, (1994), 211-222.
124. Davies NM, Kellaway IW, Greaves JL and Wilson CG; "Advanced Corneal Delivery Systems: Liposomes", Chapter 14, in Mitra AK ed., *Ophthalmic Drug Delivery Systems. Drugs and Pharmaceutical Sciences Series*, Vol. 58, Marcel Dekker, Inc., 1993, pp. 289-308.
125. Smolin G, Okumoto M, Feter S and Condon D; Idoxuridine-liposome therapy for Herpes simplex keratitis. *Am. J. Ophthalmol.* 91, (1981), 220.
126. Lin H-H, Ko S-M, Hsu L-R and Tsai Y-H; The preparation of norfloxacin-loaded liposomes and their *in-vitro* evaluation in pigs eye. *J. Pharm. Pharmacol.* 48, (1996), 801-805.
127. Durrani AM, Davis NM, Thomas M and Kellaway IW; Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system. *Int. J. Pharm.*: 88, (1982), 409-415.

128. Callegan MC, Hobden JA, O'Callaghan RJ and Hill JM; Ocular drug delivery: a comparison of transcorneal iontophoresis to corneal collagen shields. *Int. J. Pharm.* 123, (1995), 173-179.
129. Rootman DS, Hobden JA, Jantzen JA, Gonzalez JR, O'Callaghan RJ and Hill JM; Iontophoresis of tobramycin for the treatment of experimental *Pseudomonas* keratitis in the rabbit. *Arch. Ophthalmol.*; 106, (1988), 262-265.
130. Sarraf D, Equi RA, Holland GN, Yoshizumi MO and Lee DA; Transscleral iontophoresis of foscarnet. *Am. J. Ophthalmol.*; 115, (1993), 748-754.
131. Mullins J D and Fleming TC; "Quality Control of Ophthalmic Products", in Cooper MS ed., *Quality Control in the Pharmaceutical Industry. Vol. 3.*, Academic Press, NY 1979, pp. 259-285.
132. ASHP Reports: Pharmacy-prepared ophthalmic products. ASHP technical assistance bulletin on pharmacy-prepared ophthalmic products. *Am. J. Hosp. Pharm.*; 50, (1993), 1462-1463.
133. Agalloco J; A review of the U.S. FDA guideline on aseptic processing. *J. Parent. Sci. Technol.*; 46(3), (1992), 78-84.
134. Schoenwald RD Akers MJ and McGinity JW; Practical aspects of ophthalmic drug development. *Drug Dev. Ind. Pharm.* 3(3), (1977), 185-217.
135. Mullins JD and Hecht G; "Ophthalmic preparations", in Gennaro AR ed., *Remington's Pharmaceutical Sciences*. 18th edition, Mack publishing Co, 1990, pp 1581-1595.
136. Jurgens Jr. RW; Preservatives for ophthalmic products. *Drug Cos. Ind.*; Feb. 1976, 56, 58, 60.
137. Green K; The role of surfactants as bactericides in topical drug delivery. *STP Pharma Sci.*; 2(1), (1992), 34-38.
138. Richards RME and McBride RJ; The preservation of ophthalmic solutions with antibacterial combinations. *J. Pharm. Pharmacol.* 24, (1972), 145-148.
139. Conrad JM, Reay WA, Polcyn E and Robinson JR; Influence of tonicity and pH on lacrimation and ocular drug bioavailability. *J. Parent. Sci. Assoc.*; 32, (1978), 149-161.
140. "Ophthalmic Preparations", Chapter 12, in Ansel HC ed., *Introduction to Pharmaceutical Dosage Forms*, 4th edition, Lea & Febiger, 1985, pp. 321-336.

141. "Ophthalmic buffer systems", in Parrott EL and Saski W eds., *Experimental Pharmaceutical Technology*. Burgess Publishing Co., 1963, pp. 247-249.
142. Burstein NL; Preservative alteration of corneal permeability in humans and rabbits. *Invest. Ophthalmol. Vis. Sci.*: 25 (1984), 1453-1457.
143. Cohen S, Lobel E, Trevigoda A and Peled Y; A novel *in-situ* ophthalmic drug delivery system from alginates undergoing gelation in the eye. *J. Control. Rel.*: 44(2&3), (1997), 201-208.
144. Saettone MF, Chetoni P, Torracca MT, Burgalassi and Giannaccini B; Evaluation of mucoadhesive properties and *in-vivo* activity of ophthalmic vehicles based on hyaluronic acid. *Int. J. Pharm.*: 51(3), (1989), 203-212.
145. Chrai SC and Robinson JR; Ocular evaluation of methylcellulose vehicle in albino rabbits. *J. Pharm. Sci.*: 63(8), (1974), 1218-1223.
146. Li V H-K and Robinson JR; Solution viscosity effects on the ocular disposition of cromolyn sodium in the albino rabbit. *Int. J. Pharm.* 53, (1989), 219-225.
147. Saettone MF, Giannaccini B, Savigni P, Teneggi A and Tellini N; Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man. *J. Pharm. Pharmacol.*: 34, (1982), 464-466.
148. Weinreb RN and Jani R; A novel formulation of an ophthalmic beta-adrenoceptor antagonist. *J. Parent. Sci. Technol.* 46(2), (1992), 51-53.
149. Tighe B; Eye contact. *Chemistry in Britain*: March 1992, 241-244.
150. Mitra A and Mikkelsen TJ; Ophthalmic buffer systems. I. The effect of buffer concentration on ocular absorption of pilocarpine. *Int. J. Pharm.*: 10, (1982), 219-229.
151. Ahmed I and Chaudhari B; Evaluation of buffer systems in ophthalmic product development. *Int. J. Pharm.* 44, (1988), 97-105.
152. Novack GD; The development of new drugs for ophthalmology. *Am. J. Ophthalmol.*: 114(3), (1992), 357-364.
153. Draize JH, Woodward G and Calvery HO; Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. *J. Pharm. Exp. Ther.* 82, (1944), 377-390.

154. Gilman MR; "Skin and eye testing in animals" in Hays AW ed., *Principles and methods of toxicology*. Raven Press, NY 1982, pp. 209-222.
155. Salminen L and Urtti U; "Disease state models", Chapter 7, in Mitra AK ed., *Ophthalmic Drug Delivery Systems*. Drugs and Pharmaceutical Sciences Series, Vol. 58, Marcel Dekker, Inc., 1993, pp. 137-160.
156. Leibowitz HM and Kupferman A; Quantitation of bacterial infection and antibiotic effect in the cornea. *Arch. Ophthalmol.*: 94, (1976), 1981-1984.
157. Callegan MC, Hobden JA, Hill JM, Insler MS and O'Callaghan RJ; Topical antibiotic therapy for the treatment of experimental *Staphylococcus aureus* keratitis. *Invest. Ophthalmol. Vis. Sci.*: 33(11), (1992), 3017-3023.
158. Callegan MC, Engel LS, Hill JM and O'Callaghan RJ; Ciprofloxacin vs tobramycin for the treatment of *staphylococcal* keratitis. *Invest. Ophthalmol. Vis. Sci.*: 35(3), (1994), 1033-1037.
159. Sugar A, Cohen MA, Bien PA, Griffin TJ, Heifetz CL and Mehta S; Treatment of experimental *Pseudomonas* corneal ulcers with enoxacin, a quinolone antibiotic. *Arch. Ophthalmol.*: 104, (1986), 1230-1232.
160. Hatano H, Inoue K, Shia S and Liping W; Application of topical lomefloxacin against experimental *Pseudomonas* endophthalmitis in rabbits. *Acta Ophthalmol.*: 71, (1993), 666-670.
161. Park SS, Samiy N, Ruoff K, D'Amico DJ and Baker AS; Effect of intravitreal dexamethasone in the treatment of *pneumococcal* endophthalmitis in rabbits. *Arch. Ophthalmol.*: 113, (1995), 1324-1329.
162. Callegan MC, Engel LS, Hill JM and O'Callaghan RJ; Corneal virulence of *Staphylococcus aureus*: roles of alpha-toxin and protein-A in pathogenesis. *Infect. Immun.*: 62, (1994), 2478-2482.
163. Kernacki KA and Berk RS; Ocular inflammation therapy; Characterization of the inflammatory response induced by corneal infection with *Pseudomonas aeruginosa*. *J. Ocul. Pharmacol.*: 10(1), (1994), 281-288.
164. Donahue SP, Khoury JM and Kowalski RP; Common ocular infections: a prescribers' guide. *Drugs* 52(4), (1996), 526-540.
165. Limberg MB; A review of bacterial keratitis and bacterial conjunctivitis. *Am. J. Ophthalmol.*: 112, (1991), 2S-9S.

166. Steinert RF; Current therapy for bacterial keratitis and bacterial conjunctivitis. *Am. J. Ophthalmol.*: 112, (1991), 10S-14S.
167. Ogawa GSH and Hyndiuk RA; The fluoroquinolones: New antibiotics in ophthalmology. *Int. Ophthalmol. Clin.*: 33(4), (1993), 59-68.
168. Serdarevic ON; Role of the fluoroquinolones in ophthalmology. *Int. Ophthalmol. Clin.*: 33(1), Winter (1993), 163-178.
169. Borrmann LR and Leopold IH; The potential use of quinolones in future ocular antimicrobial therapy. *Am. J. Ophthalmol.*: 106(2), (1988), 227-229.
170. Jones DB; New horizons in antibacterial antibiotics. *Int. Ophthalmol. Clin.*: 33(1), (1993), 179-186.
171. Neu HC; Microbiologic aspects of fluoroquinolones. *Am. J. Ophthalmol.*: 112, (1991), 15S-24S.
172. Smith JT; Mutation rates to 4-quinolone resistance. *Arzneim.-Forsch.*: 40, (1990), 65-68.
173. Marchese AL, Slana VS, Holmes EW and Jay WM; Toxicity and pharmacokinetics of ciprofloxacin. *J. Ocul. Pharmacol.*: 9(1), (1993), 69-76.
174. Heaton JD and Hackett RB; Systemic and ocular safety of ciprofloxacin ophthalmic solution (Ciloxan[®]) in immature animals. *J. Toxicol. Cutaneous Ocul. Toxicol.*: 12(4), (1993), 273-283.
175. Weiss S; Tissue destruction by neutrophils. *New Engl. J. Med.* 320, (1989), 365-375.
176. Frangie JP and Leibowitz; Steroids. *Int. Ophthalmol. Clin.*: 33(4), Fall, (1993), 9-29.
177. Stern GA and Buttross M; Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease. *Ophthalmology*: 98(6), (1991), 847-853.
178. "Ocular anti-infective and anti-inflammatory agents", Chapter 21, in *AMA Drug Evaluations*, 5th edition, W. B. Saunders Co., 1983, pp. 481-496.
179. Dannenberg AM Jr., The anti-inflammatory effects of glucocorticoids: A brief review of the literature. *Inflammation*: 3(3), (1979), 329-343.

180. Hobden JA, O'Callaghan RJ, Hill JM, Hagenah M, Insler MS and Reidy JJ; Ciprofloxacin and prednisolone therapy for experimental *pseudomonas* keratitis. *Curr. Eye Res.*: 11(3), (1992), 259-266.
181. Badenoch PR, Hay GJ, McDonald PJ and Coster DJ; A rat model of bacterial keratitis: effect of antibiotics and corticosteroid. *Arch. Ophthalmol.*: 103, (1985), 718-722.
182. Skelly JP and Barr WH; Biopharmaceutic considerations in designing and evaluating novel drug delivery systems. *Clin. Res. Pract. Drug. Reg. Affairs* 3(4), (1985), 501-539.
183. Monograph on Ciprofloxacin, in Budavari S ed., *The Merck Index*, XII edition, 1996, Merck Research Laboratories, pp. 389-390.
184. Ross DL and Riley CM; Aqueous solubilities of some variously substituted quinolone antimicrobials. *Int. J. Pharm.*: 63, (1990), 237-250.
185. Ross DL and Riley CM; Physicochemical properties of the fluoroquinolone antimicrobials. II. Acid ionization constants and their relationship to structure. *Int. J. Pharm.*: 83, (1993), 267-272.
186. Takács-Novák K, Józán M, Hermecz I and Szász G; Lipophilicity of antibacterial fluoroquinolones. *Int. J. Pharm.*: 79, (1992), 89-96.
187. Ross DL, Elkinton SK and Riley CM; Physicochemical properties of the fluoroquinolone antimicrobials. III. 1-Octanol/water partition coefficients and their relationship to structure. *Int. J. Pharm.*: 88, (1992), 379-389.
188. Monograph on Ciprofloxacin HCl in The United States Pharmacopoeia 23rd revision, The United States Pharmacopoeial Convention, Inc., 1995, pp. 376-377.
189. Traub WH and Leonhard B; Heat stability of the antimicrobial activity of 62 antibacterial agents. *J. Antimicrob. Chemother.*: 35, (1995), 149-154.
190. Tiefenbacher E-M, Haen E, Pryzbilla B and Kurz H; Photodegradation of some quinolones used as antimicrobial therapeutics. *J. Pharm. Sci.*: 83(4), (1994), 463-467.
191. Matsumoto M, Kojima K, Nagano H, Matsubara S and Yokota T; Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation. *Antimicrob. Ag. Chemother.*: 36(8), (1992), 1715-1719.

192. Phillips G, Johnson BE and Ferguson J; The loss of antibiotic activity of ciprofloxacin by photodegradation. *J. Antimicrob. Chemother.*: 26, (1990), 783-789.
193. Tornianen K, Tammilehto S and Ulvi V; The effect of pH, buffer type and drug concentration on the photodegradation of ciprofloxacin. *Int. J. Pharm.* 132, (1996), 53-61.
194. Kane MP, Bailie GR, Moon DG and Siu I; Stability of ciprofloxacin injection in peritoneal dialysis solutions. *Am. J. Hosp. Pharm.*: 51, (1994), 373-377.
195. Williams D and Ding Z-Q; Photochemical stability of the fluoroquinolone, ciprofloxacin HCl. AAPS Annual Meeting 1994, contributed papers abstracts, Abstract No. APQ 1083.
196. Jim LK; Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. *Ann. Pharmacother.*: 27(6), (1993), 704-707.
197. Monograph on Ciprofloxacin, in Trissel LA ed., Handbook of Injectable Drugs, 8th edition, American Society of Hospital Pharmacists, 1994, pp. 257-261.
198. Domagala JM; Structure-activity and structure-side-effect relationship for the quinolone antibacterials. *J. Antimicrob. Chemother.*: 33, (1994), 685-706.
199. Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA and Ward A.; Ciprofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs*: 35, (1988), 373-447.
200. Naumann P and Dopp C; Fluoroquinolones- Antibacterial activity, pharmacokinetics and indications of a new group of drugs. *Internist*: 30(1), (1989), 20-31.
201. Davis R, Markham A and Balfour JA; Ciprofloxacin: An updated review of its pharmacology, therapeutic efficacy and tolerability. *Drugs*: 51(6), (1996), 1019-1074.
202. Wise R, Griggs and Andrews JM; Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. *Rev. Infect. Dis.*: 10(Suppl. 1), (1988), S83-S89.
203. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J and Caldwell J; Absolute oral bioavailability of ciprofloxacin. *Antimicrob. Ag. Chemother.*: 30(3), (1986), 444-446.
204. Lettieri JT, Rogge MC, Kaiser L, Echols RM and Heller AH; Pharmacokinetic profiles of ciprofloxacin after single i.v. and oral doses. *Antimicrob. Ag. Chemother.*: 36(5), (1992), 993-996.

205. Vance-Bryan K, Quay DRP and Rotschafer JC; Clinical pharmacokinetics of ciprofloxacin. *Clin. Pharmacokinet.*: 19(6), (1990), 434-461.
206. Behrens-Baumann W and Martell J; Ciprofloxacin concentrations in human aqueous humour following intravenous administration. *Chemotherapy*: 33(5), (1987), 328-330.
207. Sweeney G, Fern AI, Lindsay G and Doig MW; Penetration of ciprofloxacin into the aqueous humour of the uninflamed human eye after oral administration. *J. Antimicrob. Chemother.*: 26, (1990), 99-105.
208. Alfaro DV, Hudson SJ, Rafanan MM, Moss ST and Levy S-DP; The effect of trauma on the ocular penetration of intravenous ciprofloxacin. *Am. J. Ophthalmol.*: 122, (1996), 678-683.
209. Kees F, Raasch W, and Grobecker H; *Strukturelle charakterisierung eines unbekannten metaboliten von ciprofloxacin. Arzneim. -Forsch.*: 42, (1992), 570-575.
210. Gau W, Kurz I, Petersen U, Ploschke HJ and Wuensche C; Isolation and structural elucidation of urinary metabolites of ciprofloxacin. *Arzneim. -Forsch.*: 36(10), (1986), 1545-1549.
211. Zeller HI, Petersen U, Gau W and Ploschke HJ; Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. *Arzneim. -Forsch.*: 37(2), (1987), 131-134.
212. Pecquet S, Ravoire S and Andremont A; Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal flora in healthy volunteers. *J. Antimicrob. Chemother.*: 26, (1990), 125-129.
213. Shah A, Lettieri J, Blum R, Millikin S, Sica D and Heller AH; Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. *J. Antimicrob. Chemother.*: 38, (1996), 103-116.
214. Brouwers JRB; Drug interactions with quinolone antibacterials. *Drug Safety* 7(4), (1992), 268-281.
215. Gillum JG, Israel DS and Polk RE; Pharmacokinetic drug interactions with antimicrobial agents. *Clin. Pharmacokinet.*: 25(6), (1993), 450-482.
216. Leibowitz HM; Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. *Am. J. Ophthalmol.*: 112, (1991), 29S-33S.

217. Leibowitz HM; Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for the treatment of bacterial keratitis. *Am. J. Ophthalmol.*: 112, (1991), 34S-47S.
218. Cokington CD and Hyndiuk RA; Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. *Am. J. Ophthalmol.*: 112, (1991), 25S-28S.
219. Parks DJ, Abrams DA, Sarfarazi FA and Katz HR; Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. *Am. J. Ophthalmol.*: 115, (1993), 471-477.
220. McDermott ML, Tran TD, Cowden JW and Buggé CJL; Corneal stromal penetration of topical ciprofloxacin in humans. *Ophthalmology*: 100, (1993), 197-200.
221. Donnenfeld ED, Schrier A, Perry HD, Gombert M and Snyder R; Intraocular penetration of topically applied antibiotics into the aqueous humour. *Invest. Ophthalmol. Vis. Sci.* 34(4), (1993), Abstract No. 3908-22.
222. Rao GR, Avadhunulu AB and Vatsa DK; Spectrophotometric determination of ciprofloxacin in its dosage forms. *Indian Drugs*: 27(10), (1990), 532-535.
223. Shanbhag SG, Thampi PP and Thampi CS; A simple spectrophotometric method for the estimation of ciprofloxacin HCl and its dosage forms. *Indian Drugs*: 28(6), (1991), 279-280.
224. El Walily AFM, Belal SF and Bakry RS; Spectrophotometric and spectrofluorimetric estimation of ciprofloxacin and norfloxacin by ternary complex formation with eosin and palladium (II). *J. Pharm. Biomed. Anal.*: 14(5), (1996), 561-569.
225. Sane RT, Patel DV, Dhumal SN, Nerurkar VR, Mainkar PS and Gangal DP; HPLC determination of ciprofloxacin from pharmaceutical preparations. *Indian Drugs* 27(4), (1990), 248-250.
226. Parasrampur J and Das Gupta V; Quantitation of ciprofloxacin hydrochloride and norfloxacin in tablets using HPLC. *Drug Dev. Ind. Pharm.*: 16(9), (1990), 1597-1604.
227. Lacroix PM, Curran NM and Sears RW; High-pressure liquid chromatographic methods for ciprofloxacin hydrochloride and related compounds in raw materials. *J. Pharm. Biomed. Anal.*: 14(5), (1996), 641-654.

228. Awni-Walid M, Clarkson J and Guay-David RP; Determination of ciprofloxacin and its 7-ethylenediamine metabolite in human serum and urine by HPLC. *J. Chromatogr.*: 419, (1987), 414-20.
229. Myers CM, Blumer JL; HPLC determination of ciprofloxacin and its metabolites in serum, urine and sputum. *J. Chromatogr.*: 422, (1987), 153-164.
230. Nilsson-Ehle I; Assay of ciprofloxacin and norfloxacin in serum and urine by HPLC. *J. Chromatogr.*: 416, (1987), 207-211.
231. Basci NE, Bozkurt A, Kalayci D and Kayaalp SO; Rapid liquid chromatographic assay of ciprofloxacin in human aqueous humour. *J. Pharm. Biomed. Anal.*: 14(3), (1996), 353-356.
232. Groeneveld AJN and Brouwers JRB; Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by HPLC. *Pharm. Weekbl. Sci. ed.*: 8(1), (1986), 79-54.
233. Vallee F, LeBel M and Bergeron MG; Determination of ciprofloxacin in biological samples by RP-HPLC. *Therap. Drug Monit.*: 8(3), (1986), 340-345.
234. Mehta AC, Hart-Davies S and Kay EA; HPLC determination of ciprofloxacin in plasma. *J. Clin. Pharm. Ther.*: 17, (1992), 117-120.
235. Chan CY, Lam AW and French GL; Rapid HPLC assay of fluoroquinolones in clinical specimens. *J. Antimicrob. Chemother.*: 23, (1989), 597-604.
236. Monograph on Dexamethasone in Budavari S ed., *The Merck Index*, XII edition, 1996, Merck Research Laboratories, pp. 498-499.
237. Cohen EM; Dexamethasone - a monograph in Florey KP ed., *Analytical Profiles of Drug Substances*, Vol. 2, pp. 163-199, 1973. Academic Press NY.
238. Carmichael TR, Gelfand Y and Welsh NH; Topical steroids in the treatment of central and paracentral corneal ulcers. *Br. J. Ophthalmol.*: 74, (1990), 528-531.
239. Roth JA and Kaeberle ML; Effects of *in vivo* dexamethasone administration on *in vitro* bovine polymorphonuclear leukocyte function. *Infect. Immun.*: 33, (1981), 434-441.
240. Leibowitz HM and Kupferman A; Topically administered corticosteroids: Effects on antibiotic-treated bacterial keratitis. *Arch. Ophthalmol.*: 98, (1980), 1287-1290.

241. Krupin T, Waltman SR and Bernard B; Ocular penetration in rabbits of topically applied dexamethasone. *Arch. Ophthalmol.*: 92, (1974), 312-314.
242. Short C, Keates RH, Donovan EF, Wyman M and Murdick PW; Ocular penetration studies. I. Topical administration of dexamethasone. *Arch. Ophthalmol.*: 75, (1966), 689-692.
243. Loftsson T, Fridriksdóttir H, Thórisdóttir S and Stefánsson E; The effect of hydroxypropylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl- β -cyclodextrin formulations. *Int. J. Pharm.*: 104, (1994), 181-184.
244. Santoni G, Tonsini A, Gratteri P, Mura P, Furlanetto S and Pinzauti S; Determination of atropine sulphate and benzalkonium chloride in eye drops by HPLC. *Int. J. Pharm.*: 93, (1993), 239-243.
245. DiBiase MD and Rhodes CT; Formulation and evaluation of epidermal growth factor in Pluronic F-127 gel. *Drug Dev. Ind. Pharm.*: 22(8), (1996), 823-831.
246. "Rheology" Chapter 17, in Martin A. ed. *Physical Pharmacy* 4th edition, Waverly BI publishers, 1994, pp. 453-476.
247. Bothner H, Waaler T and Wik O; Rheological characterization of tear substitutes. *Drug Dev. Ind. Pharm.*: 16(5), (1990), 755-768.
248. Jansen T, Xhonneux B, Mesens J and Borgers M; Beta-cyclodextrins as vehicles in eye-drop formulations: An evaluation of their effects on rabbit corneal epithelium. *Lens and Eye Toxicity Research*: 7(3&4), (1990), 459-468.
249. Loftsson T and Stefánsson E; Effect of cyclodextrins on topical drug delivery to the eye. *Drug Dev. Ind. Pharm.*: 23(5), (1997), 473-481.
250. Loftsson H, Stefánssdóttir O, Fridriksdóttir H and Gudmundsson Ö; Interactions between preservatives and 2-hydroxypropyl- β -cyclodextrin. *Drug Dev. Ind. Pharm.*: 18(13), (1992), 1477-1484.
251. Suhonen P, Jarvinen T, Lehmussaari K, Reunamaki T and Urtti A; Ocular absorption and irritation of pilocarpine is modified with buffer, polymer and cyclodextrin in the eyedrop. *Pharm. Res.* 12(4), (1995), 529-540.
252. Gilman MR, "Skin and eye testing in animals" in Hayes AW ed. *Principles and methods of toxicology*. Raven Press NY, 1986, pp. 209-212.

253. Tommila P, Summanen P and Tervo T; Cortisone, heparin and argon laser in the treatment of corneal neovascularization. *Acta Ophthalmol.* 65(Suppl.), (1987), 182(89-92).
254. Parke A, Bhattacharjee P, Palmer RMJ and Lazarus NR; Characterization and quantification of copper sulphate induced vascularization of the rabbit cornea. *Am. J. Pathol.* 130(1), (1988), 173-178.
255. Nikolic L, Friend J, Taylor S and Thoft RA; Inhibition of vascularization in rabbit corneas by heparin-cortisone pellets. *Invest. Ophthalmol. Vis. Sci.* 27(4), (1986), 449-456.
256. Aarons L; Sparse data analysis. *Eur. J. Drug Metab. Pharmacokinet.*: 18(1), (1993), 97-100.
257. Nedelman JR, Gibiansky E and Law DTW; Applying Bailer's method for AUC confidence intervals to sparse sampling. *Pharm. Res.*: 12(1), (1995), 124-128.
258. Bailer A.J.; Testing for the equality of AUC when using destructive measurement techniques. *J. Pharmacokinet. Biopharm.*: 16(3), (1988), 303-309.